MAY 15 2026
Krystal Biotech — Vyjuvek (beremagene geperpavec) $KRYS
for dystrophic epidermolysis bullosa
MHRA approved beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa.
About
Dystrophic epidermolysis bullosa (DEB) is an inherited condition that causes fragile skin prone to painful blisters and wounds from minor friction or trauma. Vyjuvek is a topical gene therapy that delivers functional copies of the COL7A1 gene directly to skin cells, helping them produce the collagen needed to strengthen skin layers. By restoring this structural protein, Vyjuvek may reduce blistering and improve wound healing in DEB patients.
Pivotal trial
This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Vyjuvek
- Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)? - simplywall.st
- Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)? - Sahm
- The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability - Sahm
- Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK - AD HOC NEWS
- Krystal Biotech receives UK approval for gene therapy VYJUVEK - Investing.com